Introduction {#s1}
============

The use of mesenchymal stem cells/multipotent stromal cells (MSCs) has been studied in the clinical context of tissue regeneration and cell therapy for many years due to their ability to differentiate into multiple cell types \[[@B1]--[@B3]\]. In addition, MSCs secrete a variety of supportive cytokines and matrices that promote regenerative processes, particularly factors that induce neovascularization (vascular endothelial growth factor α \[VEGF-α\], insulin-like growth factor 1 \[IGF-1\], etc.) \[[@B4], [@B5]\]. These cells also have a documented immune privilege in an undifferentiated state, as well as the ability to modulate the local host inflammatory response itself, allowing them to temporarily quell host reactions before being rejected themselves \[[@B6]--[@B8]\].

Many therapeutically relevant contexts for MSCs involve implantation of MSCs into wound sites or tissues, in which the MSCs are immediately subjected to harsh conditions or degenerative tissue. Numerous studies have reported less than 50% survival of implanted cells after only the first 48 hours, with virtually no detectable MSCs remaining after 1--2 weeks \[[@B9]--[@B11]\], despite reports of greater resistance to death from high metabolic flexibility \[[@B12]\]. We have found that MSC survival can be enhanced by restricting signaling through the epidermal growth factor receptor (EGFR) to that subset of pathways activated from the cell membrane \[[@B13]--[@B15]\]. This approach of covalently tethering epidermal growth factor (EGF) has led to in vitro improvement of MSC survival in the face of death stimuli such as Fas ligand \[[@B15], [@B16]\] while maintaining the functional capacity of the MSCs to differentiate \[[@B17]\]. For in vivo functionality, tethered epidermal growth factor (tEGF) needs to be functionalized to materials compatible with in vivo wound situations. Here, we applied this system of tethered EGF to a clinically relevant scaffold for bone healing, β-tricalcium phosphate (β-TCP), by using a high-affinity multimeric binding peptide to link soluble EGF to the scaffold. The effect on survival was then determined in a hypoxic, nonvascularized environment of a collagen plug in immunocompetent mice.

Materials and Methods {#s2}
=====================

Scaffold With tEGF Binding Peptide
----------------------------------

The high-affinity linker peptide used to bind soluble EGF to the tricalcium phosphate (TCP) surfaces was fabricated by Jaime Rivera in the Griffith Laboratory at the Massachusetts Institute of Technology (Cambridge, MA, <http://web.mit.edu/>) as described in detail in the [online supplemental data](http://stemcellstm.alphamedpress.org/lookup/suppl/doi:10.5966/sctm.2015-0217/-/DC1) \[[@B18]\]. β-Tricalcium phosphate powder consisting of 63--106 µM β-TCP particles were fabricated at Integra LifeSciences (Plainsboro, NJ, <http://www.integralife.com>) and were used for all studies as a scaffold for MSC seeding. Briefly, a human EGF sequence was inserted into a pMAL expression cassette (New England BioLabs, Ipswich, MA, <https://www.neb.com>) via polymerase chain reaction (PCR) mutagenesis to yield a library of multimer insertions fused to EGF. This protein was expressed in *Escherichia coli* and induced with isopropyl β-D-1-thiogalactopyranoside to yield protein for harvest via maltose binding protein affinity chromatography and purified using ultrafiltration and sterile syringe filtration. Reported purity of the full-length binding peptide ranged from 75%--90%. Protein concentration was measured via Nanodrop ND-2000 (Thermo Fisher Scientific, Minneapolis, MN, <https://www.thermofisher.com>) and provided to our group at the University of Pittsburgh for use in vivo.

β-Tricalcium phosphate powder consisting of 63--106 µM β-TCP particles (average 82 µM) was used for all studies as a scaffold for MSC seeding. For each individual plug, 10 mg of β-TCP powder was weighed and placed into separate tubes. For the experimental tEGF group, 10 mg β-TCP was incubated with 200 µl of 2 µM EGF/binding peptide solution for 24 hours at 4°C. Following incubation, the residual protein solution was aspirated and, for those scaffolds receiving MSCs, CM-DiI-tracked MSCs were trypsinized and added individually to both the tEGF and untreated β-TCP sample tubes at a concentration of 1.5 × 10^6^ MSCs in 1 ml proliferation media per sample. Individual samples were rotated at 37°C for 90 minutes to allow attachment of the MSCs to the β-TCP scaffolds as previously described \[[@B19], [@B20]\]. Following cell attachment, samples were gently spun to collect all β-TCP particles, and proliferation media were aspirated. The samples were then gently mixed with a 1:1 volume mixture (0.5 ml each; 1 ml total plug volume) of growth factor-reduced Matrigel (BD Biosciences, San Jose, CA, <http://www.bdbiosciences.com>) and collagen I (3.84 mg/ml) to form a viscous injectable plug.

MSC Inoculations
----------------

Primary human bone marrow-derived MSCs, used before passage 7, were obtained from the NIH-funded core facility run by Dr. Darwin Prockop at Texas A&M University. Primary MSCs were tracked using a red CM-DiI cell tracker (Thermo Fisher Scientific, Minneapolis, MN, [https://www.thermofisher.com](https://thermofisher.com)); after 12 hours red fluorescence at the MSC cell membranes was confirmed in each dish before use in vivo. The CM-DiI-tracked MSCs were trypsinized and added individually to both the tEGF and untreated β-TCP sample tubes at a concentration of 1.5 × 10^6^ MSCs as previously described \[[@B19], [@B20]\]. Following cell attachment, samples were gently spun to collect all β-TCP particles, and proliferation media were aspirated. Both MSC and non-MSC TCP and tEGF-TCP samples were then gently mixed with a 1:1 volume mixture (0.5 ml each; 1 ml total plug volume) of growth factor-reduced Matrigel (BD Biosciences) and collagen I (BD Biosciences) (3.84 mg/ml) on ice to form a viscous injectable plug.

Immunocompetent FVB mice that were 8--10 weeks old were obtained from Jackson Laboratories (Bar Harbor, ME, <https://www.jax.org>). For injection, the collagen I/Matrigel mixtures containing TCP (described in the previous section) were transferred into the perifascial space above the quadriceps on each leg, with 1 ml of gel injected transcutaneously on the anesthetized mice. Mice were treated at the time of inoculation with Buprenorphine SR (ZooPharm, Fort Collins, CO, <http://wildpharm.com/zoopharm-home.html>) to prevent pain; observational follow-up did not present signs of pain from the procedure. Plugs solidified immediately in vivo and were extracted at each time point following mouse euthanization via CO~2~ asphyxiation. All animal work was reviewed and approved by the Pittsburgh VA Medical Center and the University of Pittsburgh Institutional Animal Care and Use Committees.

Results {#s3}
=======

To assess the ability of tEGF to improve immediate and long-term MSC survival, we applied tEGF to clinically relevant β-TCP particles and seeded MSCs on these scaffolds mixed into a gel plug for injection into the perifascial space of immunocompetent mice above the quadriceps muscle ([Fig. 1A](#F1){ref-type="fig"}). MSC-TCP scaffolds seeded with CM-DiI-tracked MSCs were gently suspended in a 1:1 mixture of collagen I and Matrigel to provide a gel for scaffold injection into the perifascial site, with gel plugs removed after 1, 3, 7, and 21 days of incubation in vivo ([Fig. 1B](#F1){ref-type="fig"}).

![Experimental schematic for tEGF plug injections. **(A)**: Tracked (CM-DiI) primary bone marrow-derived human MSCs were seeded onto tricalcium phosphate particles with or without soluble EGF tethered to the scaffold surface via rotation in proliferation media (also see Methods). The seeded TCP scaffolds were mixed into a 1:1 collagen I/Matrigel gel mixture and injected into the perifacial space of FVB mice above the quadriceps. **(B)**: Plugs were extracted on days 2, 7, and 21 for cryosectioning and flow cytometry analyses. Abbreviations: β-TCP, β-tricalcium phosphate; EGF, epidermal growth factor; MSCs, mesenchymal stem cells/multipotent stromal cells; TCP, tricalcium phosphate; tEGF, tethered epidermal growth factor.](sctm_20150326_f1){#F1}

At each time point, half of each gel plug was fixed and cryosectioned to determine the distribution of the TCP particles and MSCs throughout each gel scaffold, as well as monitor the survival of the CM-DiI-tracked MSCs with time ([Fig. 2](#F2){ref-type="fig"}). Sections showed a generally even distribution of MSCs throughout all implants, with tracked MSCs localizing in the vicinity of the β-TCP particle aggregates, as expected ([Figs. 2A, 2C](#F2){ref-type="fig"}). Fluorescent signal from the tracked MSCs appeared to be more prevalent in the tEGF-modified TCP conditions compared with the standard TCP scaffold conditions. tEGF scaffolds also improved the apparent angiogenic character of the plugs, as can be seen in the extracted plugs in [Figure 1B](#F1){ref-type="fig"}.

![Surface tEGF improves MSC survival on β-tricalcium phosphate scaffolds. Extracted plugs were digested and cells were isolated for flow cytometry analysis, using MSC markers CD73 and CD90 to identify the human MSCs. **(A)**: Shown are mean ± standard deviation of five to six mice; ∗, *p* \< .01, \#, *p* \< .05. Half of each plug was also cryosectioned and analyzed for presence of general cells (DAPI, actin stains) and visual presence of MSCs shown at 21 days at low magnification **(B)** and within the TCP particles themselves at higher magnification **(C)**. Shown are representative of plugs from five to dix mice, in two separate experiments. Magnification = ×20 objective for ×200-fold magnification. Abbreviations: MSC, mesenchymal stem cell/multipotent stromal cell; TCP, tricalcium phosphate; tEGF, tethered epidermal growth factor.](sctm_20150326_f2){#F2}

MSC survival was quantified via flow cytometry analysis of MSC presence using common human MSC markers CD73 and CD90 ([Fig. 2A](#F2){ref-type="fig"}) following plug digestion. Percent positive MSC populations were derived from total cell harvests from all plugs at the aforementioned time points, and MSC percentages from flow cytometry were then applied to the total cell count from each plug to estimate the number of MSCs present in each half-plug; if the cells had fully differentiated, we would have not noted them, but their survival would not be expected due to the species difference in an immunocompetent animal. In the course of two experiments, results show that tEGF-TCP scaffolds provide a distinct survival advantages to implanted MSCs at all assayed time points. Days 3 and 7 showed an approximately fourfold improvement in remaining MSCs over the TCP scaffold alone. This survival effect is perhaps most notable in the long term, where a significant portion of the MSCs persist out to 21 days.

Cellularity is often a point of interest in regenerative scaffolds, owing to the importance of invading CD31^+^ cells and proliferation of any native cells that might be participating in the regenerative response. We assessed total cell counts from extracted plugs during the processing of each plug for flow analysis via automated cell counting. We found that the presence of tEGF on the TCP scaffolds significantly increased the total number of isolated cells within each plug, particularly at days 7 and 21; at these extended times the tEGF conditions showed a drastic increase in cellularity, well above the cellularity that would come from the implanted MSCs alone ([Fig. 3A](#F3){ref-type="fig"}). This increased cellularity represented an almost twofold to threefold increase over the unmodified TCP scaffolds. At day 7, there were 3.89 ± 0.13 × 10^6^ cells on the tEGF particles at day 7 compared with 1.74 ± 0.28 ×10^6^ cells on TCP alone. Notably, the increased numbers of cells was noted with an apparent increase in the vascularity of each plug; unfortunately, the process of histochemistry for visualization of the TCP scaffolds prevented definitive immunohistochemical detection of the vessels. TCP scaffolds without tEGF showed a slight upward trend in cellularity within 21 days, roughly doubling the initial 1 million identified cells at the day 2 time point.

![Improved MSC survival on tethered epidermal growth factor scaffolds increases overall cellularity with no overt effect on inflammatory infiltration. **(A)**: Digested plugs from each time point were counted using a Sceptre cell counter, and total cell counts were recorded and extrapolated to yield an estimated cell count for the entire extracted plug at each time point. Cell counts are reported here as those estimates, before MSC identification and thus including the whole cell extract from the mouse, as well as any MSCs left in the plug. In addition, percent positive for murine markers of inflammation including CD11b **(B)**, Nk1.1 **(C)**, and CD3e **(D)** were determined via flow cytometry and percentages were extrapolated back to cell counts to determine an estimated number of invading cells for each marker. A Student's *t* test was performed to determine significance, mean ± standard error, from five to six mice; ∗, *p* \< .01, \#, *p* \< .05. Abbreviation: MSC, mesenchymal stem cells/multipotent stromal cell.](sctm_20150326_f3){#F3}

Differences in cellularity were potentially attributable to invading murine cells via innate immunity or paracrine functions of the MSCs themselves. We therefore analyzed whole cell extracts from the injected plugs for the presence of murine CD11b^+^ (pan-leukocyte), Nk1.1^+^ (natural killer T cells), and/or CD3e^+^ (T-cell receptor) cells ([Figs. 3B, 3C, 3D](#F3){ref-type="fig"}). Results showed that invading cells were primarily composed of murine cells positive for the pan-leukocyte marker CD11b ([Fig. 3B](#F3){ref-type="fig"}), with a slight increase at early time points for ^+^tEGF injections. Nk1.1 and Cd3e^+^ cells represented a minor portion of invading cells, with little difference demonstrated ^+/−^ tEGF in either of these subsets; this T-cell infiltration increase is as expected for acquired immunity rejection of the transplanted human cells.

Discussion {#s4}
==========

Our group has previously examined the benefit of EGF tethering largely in vitro, showing enhanced survival in the face of Fas ligand challenge \[[@B16], [@B17], [@B21]\]. Here, we have built on work by Alvarez and Rivera \[[@B18]\] in designing this peptide and examining effects in vivo, attempting to challenge MSCs in an implant site and hypothesizing that EGF tethering would provide a protective effect in this context. Results from this study demonstrate the utility of surface tethering soluble EGF to scaffolds for MSC implantation in such an environment. Our chosen implant site, the perifascial space above the quadriceps, was largely devoid of blood flow or a nutrient supply, highly hypoxic compared with the culture environment and thus similar to a wound bed. Thus, these cells were initially faced with a nutrient-poor and hypoxic environment within the plug itself, specifically chosen to mimic the harsh wound environment these cells would typically be exposed to upon injection. The immunocompetent nature of the animals was chosen for two reasons: first to demonstrate increased survival even in the face of immunological challenge, and second as a model for allogenic transplantation should the extended lifespan prove sufficient to "educate" a wound bed to improve healing from endogenous MSCs. We also subjected the cells to any relevant innate and acquired immune responses, as we used immunocompetent mice for our xenotransplant.

Our data show that a modest concentration of surface-tethered EGF is able to keep up to 30% of implanted MSCs alive even 21 days following injection into a region generally devoid of vessel growth and nutrients for the cells ([Fig. 2](#F2){ref-type="fig"}), significantly more than clinical studies have shown for typical MSC survival in vivo \[[@B9]--[@B11]\]. Although a majority of the cells have still indeed died at the end of this study, a 3-week lifespan is sufficient for these cells to have started and proceeded well into the process of differentiation. Although we have shown that tEGF substrates have a positive effect on the osteogenic potential of MSCs in vitro \[[@B17]\], follow-up studies are necessary to look further at the efficiency of MSC osteodifferentiation in vivo and translate improved survival to a possible clinical benefit. The present study was not designed to determine whether the tEGF increased seeding, survival, and/or subsequent proliferation of the MSCs in vivo. Such information awaits further work, now that we found enhanced MSCs in the inoculated plugs. In addition, a significant limitation of this study is the lack of clarity on the fate of the surviving cells. Although we do show presence and persistence of the human MSCs long term, it is yet unclear if some of the inoculated cells migrated from the plug space or differentiated in situ. Future studies will require a more in-depth exploration of the fate of the surviving MSCs, as well as the more specific paracrine effects on invading host cells beyond those analyzed here to rule out any nontargeted EGFR activation.

Analyses of total cell counts from extracted plugs in this study showed increased cellularity in those scaffolds with the tEGF binding peptide, including all extracted murine and human cells. Although this is partially due to the improved survival of MSCs on these scaffolds as reported in [Figure 2](#F2){ref-type="fig"}, these data also highlight the likelihood that MSCs maintain paracrine function with the constitutive EGFR activation induced on our tEGF scaffolds. For example, MSCs have long been known to be important in inducing angiogenesis locally via VEGF activity, improving vessel formation in tube formation assays \[[@B22]\] and also showing increased angiogenesis in implant sites in vivo in a wound healing context \[[@B23]\]. Flow cytometry analysis of several murine markers of inflammation demonstrated a clear cellular invasion after implant, largely composed of murine cells positive for pan-leukocyte marker CD11b. However, little difference in the number of invading cells was seen between TCP controls and ^+^tEGF test groups, suggesting that another potential invading cell or another paracrine function of the implanted MSCs may be responsible for the trends in cellularity. Still, the numbers of MSCs and leukocytes combined account for much less than half of the total cell number in the presence of tEGF, although totaling up to approximately two thirds of the cells in the control condition; this suggests that other cells are involved. An untested cell type would be those of the vascular system, which would explain the seeming increased vascularity as noted by visual inspection of the implants that had tEGF. Our group has previously shown in vitro that sustained EGFR activation through tethering approaches may improve paracrine function of MSCs through upregulation of growth factor and/or cytokine production \[[@B24]\]. Future studies with EGF tethering and MSCs must discern the effects of EGFR tethering on the MSC secretome and associated outcomes in the implant site, both beneficial and otherwise.

Given its role in a wide array of cellular processes, it stands to reason that our persistent activation of EGFR may have effects beyond enhanced cell survival. Although survival signaling via EGFR functions primarily through the PI3K/Akt signaling arm \[[@B25], [@B26]\], there are other aspects to EGFR signaling that might benefit the MSCs in a clinical context. A variety of studies in EGFR tethering have shown, for example, enhanced MSC proliferation in concert with the improved survival we have seen in this study \[[@B18], [@B27]\]. Although enhanced proliferation may help to simply increase the number of available MSCs after implantation and improve overall survival outcomes, increased proliferation of MSCs long term may assist with MSC-derived osteoblast migration into a bone defect site or other comparable scenarios where proliferation is of importance. In addition, cell motility is intimately tied into the EGFR signaling cascade \[[@B28], [@B29]\], and a multitude of studies have shown the effects of EGFR activation on enhanced migration. Although surface-restricted EGFR signaling has shown to yield outcomes for improved survival preferentially over migration \[[@B27], [@B30]\], the benefits of any enhanced MSC motility from this construct may assist with cell engraftment and ultimately regenerative outcomes in the implant site.

Conclusion {#s5}
==========

Due to its relatively straightforward design and the ubiquitous expression of EGFR on many cell types, the EGF tethering system has a wide array of potential applications in regenerative medicine. Growth factor tethering (and specifically EGF tethering) has been used in a variety of contexts, including improving survival of other cell types such as vascular smooth muscle cells \[[@B31]\] or targeted therapeutic growth factor delivery \[[@B32], [@B33]\]. In the context of MSC clinical utility, although this study analyzed the effects of tEGF on a construct designed primarily for bone regeneration, the applications of EGF tethering may also extend outside of tricalcium phosphate scaffolds and bone repair in general.
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